bioRxiv · 10.1101/2023.03.09.531229
Discovery of 1,3,4-oxadiazoles with slow-action activity against Plasmodium falciparum malaria parasites
Abstract
To achieve malaria eradication, new preventative agents that act differently to front-line treatment drugs are needed. To identify potential chemoprevention starting points we screened a sub-set of the CSIRO Australia Compound Collection for compounds with slow-action in vitro activity against Plasmodium falciparum. This work identified N,N-dialkyl-5-alkylsulfonyl-1,3,4-oxadiazol-2-amines as a new antiplas-modial chemotype (e.g., 1 96 h IC50 550 nM) with a different action to delayed-death slow-action drugs. Structure activity relationship analysis of analogues identified multiple compounds with potent and selective in vitro activity against drug-sensitive and multi-drug resistant Plasmodium parasites (e.g., 31 and 32 96 h IC50 <40 nM; SI >2,500). However subsequent studies in mice with lead compound 1, which had the best microsomal stability of the compounds assessed, demonstrated rapid clearance (T1/2 <1.6 h) and poor oral in vivo efficacy. This indicates that improvements in the pharmacokinetic profile of N,N-dialkyl-5-alkylsulfonyl-1,3,4-oxadiazol-2-amines would be needed for the development of this chemotype for malaria chemoprophylaxis.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Andrews, K. T., Fisher, G. M., Firmin, M., Liepa, A., Wilson, T., Gardiner, J., Mohri, Y., Rai, A., Davey, A. K., Masurier, A., Delion, A., Mouratidis, A. A., Hutt, O., Burrows, J. N., Ryan, J. H., Riches, A., Skinner-Adams, T. S.. 2023-03-10. Discovery of 1,3,4-oxadiazoles with slow-action activity against Plasmodium falciparum malaria parasites. https://doi.org/10.1101/2023.03.09.531229
Cite the original work for its findings. Save a collection to share your selection of sources.